Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | XDH | P47989 | 3/20 | 0.43 |
| ▸ | NGFR | P08138 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ULK1 | O75385 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11807432 | 0.73 | GLA (0.68) | CYP1A2GAAGLAXDHNGFR | |
| SCHEMBL11723446 | 0.72 | GPR35 (0.68) | CYP1A2GAAGLAXDHNGFR | |
| SCHEMBL11638566 | 0.72 | GLA (0.58) | CYP1A2GAAGLAXDHNGFR | |
| SCHEMBL11409016 | 0.72 | GAA (0.66) | CYP1A2GAAGLAXDHNGFR | |
| SCHEMBL118496 | 0.72 | CYP1A2 (1.00) | CYP1A2GAAGLAXDHKDM4E | |
| SCHEMBL11725265 | 0.71 | GLA (0.57) | CYP1A2GAAGLAXDHNGFR | |
| SCHEMBL11721616 | 0.71 | GLA (0.61) | CYP1A2GAAGLAXDHNGFR | |
| SCHEMBL11639956 | 0.71 | GLA (0.57) | CYP1A2GAAGLAXDHNGFR | |
| SCHEMBL11713151 | 0.70 | NGFR (0.51) | CYP1A2GAAGLAXDHNGFR | |
| SCHEMBL15865616 | 0.69 | CYP1A2 (0.62) | CYP1A2GAAGLAXDHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396322-B9 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-09-14 | — | — | EP | disclosed |
| EP-2396322-B9 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-09-14 | — | — | EP | disclosed |
| EP-2396322-B1 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-02-03 | — | — | EP | disclosed |
| EP-2396322-B1 | 2-Morpholino-pyrido[3,2-d]pyrimidines | MERCK SERONO SA (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-8609666-B2 | 2-morpholino-pyrido[3,2-D]pyrimidines | MERCK SERONO SA (CH) | 2013-12-17 | — | — | US | disclosed |
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2011-12-01 | — | — | US | disclosed |
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2011-12-01 | — | — | US | disclosed |
| US-8058289-B2 | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | MERCK SERONO SA (CH) | 2011-11-15 | — | — | US | disclosed |
| US-8058289-B2 | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | MERCK SERONO SA (CH) | 2011-11-15 | — | — | US | disclosed |
| EP-1786812-B1 | PYRIDINE METHYLENE AZOLIDINONES AND THEIR USE AS PHOSPHOINOSITIDE INHIBITORS | MERCK SERONO SA (CH) | 2011-11-09 | — | — | EP | disclosed |
| US-7842698-B2 | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | MERCK SERONO S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7842698-B2 | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | MERCK SERONO S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7842698-B2 | Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors | MERCK SERONO S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| WO-2010091996-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010037765-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-04-08 | — | — | WO | disclosed |
| US-20080269227-A1 | Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-20080269227-A1 | Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-20080269227-A1 | Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| EP-1786812-A1 | PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024666-A1 | PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269227-A1 | Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors | PIK3CD, PIK3CA, PIK3CB | CYP1A2 2519/4885GAA 4501/4885GLA 4262/4885 |
| US-20110293564-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | PIK3CA, PIK3CD, PIK3CB | CYP1A2 2809/4885GAA 2243/4885GLA 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.